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Abstract
Introduction: The majority of breast tumors at primary diagnosis are estrogen receptor positive (ER+). Estrogen (E)
mediates its effects by binding to the ER. Therapies targeting the estrogenic stimulation of tumor growth reduce
mortality from ER+ breast cancer. However, resistance remains a major clinical problem.
Methods: To identify molecular mechanisms associated with resistance to E-deprivation, we assessed the temporal
changes in global gene expression during adaptation to long-term culture of MCF7 human breast cancer cells in the
absence of estradiol (E2), long term estrogen deprived (LTED), that leads to recovery of proliferative status and models
resistance to an aromatase inhibitor (AI). The expression levels of proteins were determined by western blotting.
Proliferation assays were carried out using the dual platelet derived growth factor receptor (PDGFR)/Abelson tyrosine
kinase (Abl) inhibitor nilotinib. Luciferase reporter assays were used to determine effects on ER-mediated transactivation.
Changes in recruitment of cofactors to the gene regulated by estrogen in breast cancer 1 (GREB1) promoter were
determined by chromatin immunoprecipitation (ChIP). Gene expression data were derived from 81 postmenopausal
women with ER+ BC pre-treatment and at two-weeks post-treatment with single agent anastrozole in a neoadjuvant trial.
Results: The PDGF/Abl canonical pathway was significantly elevated as early as one week post E-deprivation (P = 1.94
E-04) and this became the top adaptive pathway at the point of proliferative recovery (P = 1.15 E-07). Both PDGFRb and
Abl protein levels were elevated in the LTED cells compared to wild type (wt)-MCF7 cells. The PDGF/Abl tyrosine kinase
inhibitor nilotinib, suppressed proliferation in LTED cells in the presence or absence of E. Nilotinib also suppressed ER-
mediated transcription by destabilizing the ER and reducing recruitment of amplified in breast cancer-1 (AIB1) and the
CREB binding protein (CBP) to the promoter of the E-responsive gene GREB1. High PDGFRb in primary ER+ breast
cancer of 81 patients prior to neoadjuvant treatment with an AI was associated with poorer antiproliferative response.
Additionally PDGFRb expression increased after two weeks of AI therapy (1.25 fold, P = 0.003).
Conclusions: These preclinical and clinical data indicate that the PDGF/Abl signaling pathway merits clinical
evaluation as a therapeutic target with endocrine therapy in ER+ breast cancer.
Introduction
At primary diagnosis nearly 80% of breast cancers
express estrogen receptor alpha (ERa) and proliferate in
response to estrogen (E) [1]. Estrogen mediates its
effects by binding to the ER, which subsequently
associates with estrogen response elements (ERE) on
target genes controlling proliferation and survival [2].
Classically, patients with ER+ breast cancer have been
treated with endocrine agents, such as tamoxifen, which
compete with E for the ER or aromatase inhibitors (AI),
which block the conversion of androgens to estrogens
[3]. Despite the efficacy of endocrine agents, both de
novo and acquired resistance remain a significant clinical
problem with up to 40% of patients relapsing on
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tamoxifen [4]. Although it was hoped that resistance to
AIs would be less of a problem, many patients treated
with AIs also exhibit resistance [4].
The molecular events that determine changes in the
efficacy of endocrine therapies are not fully understood
[5,6]. Preclinical and clinical studies provide support for
mechanisms that involve cross-talk between ER and
growth factor signaling pathways such as ERBB2/HER2
[5-7] but this is only overexpressed in about 10% of ER+
patients and is infrequently overexpressed with acquisi-
tion of resistance [8] indicating that alternative underly-
ing molecular events remain to be discovered. In vitro
models of resistance to endocrine therapy have relied on
comparing the endocrine resistant cell lines with their
isogenic wild type (wt) [9-16]. While this has provided
valuable information highlighting many alterations in
cell signaling, it has not addressed the temporal changes
in genotype/phenotype that are directly associated with
the acquisition of resistance. We used global gene
expression analysis to assess the time-dependent
changes in gene expression during the acquisition of
resistance to estrogen deprivation using the ER+ breast
cancer cell line MCF7. These data revealed the platelet
derived growth factor (PDGF)/Ableson (Abl) canonical
pathway as significantly upregulated as early as one-
week post-estrogen deprivation and revealed this to be
the top adaptive pathway at the point of full resistance.
In studies of molecular changes occurring in tumors in
a cohort of patients treated with an AI in the neoadju-
vant setting we found PDGFRb expression to be signifi-
cantly associated with poor antiproliferative response to
therapy. Finally nilotinib, a selective inhibitor of PDGF/
Abl signaling was antiproliferative in LTED but not wt-
MCF7 cells. These laboratory and clinical studies indi-
cate that the PDGF/Abl signaling pathway is worthy of
clinical targeting to reverse or restrict resistance to AIs.
Materials and methods
Cell culture and generation of the LTED cell line
The human ER-positive breast cancer cell line MCF7,
obtained from American Type Culture Collection (Rock-
ville, MD, USA), was cultured in phenol red-free Ros-
well Park Memorial Institute medium (RPMI) medium
supplemented with 10% fetal bovine serum, 10 μg/ml
insulin and 1nM estradiol (E2) and was referred to as
wild-type MCF7. The wt-MCF7 cells were passaged
weekly and medium was replenished every two to three
days. To model acquisition of resistance to long term
estrogen deprivation (LTED) on an AI, wt-MCF7 cells
were cultured in phenol red-free RPMI medium supple-
mented with 10% dextran charcoal-stripped bovine
serum (DCC) [17] and 10 μg/ml insulin. Monolayers
were harvested at the time points indicated during
acquisition of resistance. Over a period of 40 weeks
LTED strains were generated in three independent
experiments. For mechanistic studies LTED cells were
passaged weekly and medium was replenished every two
to three days. For all functional analysis cells were
stripped of steroids and insulin over three days by cul-
turing in phenol red-free RPMI 1640 supplemented with
10% DCC referred to as DCC-medium.
Gene expression microarray analysis of cell lines
RNA was extracted from the LTED monolayers using
RNeasy columns (Qiagen, Crawley, UK) according to
the manufacturer’s protocol. RNA amplification, label-
ing and hybridization on HumanWG-6 v3 Expression
BeadChips (Illumina, San Diego, CA, USA) were per-
formed according to the manufacturer’s instructions
[18] to assess changes in gene expression during adap-
tation to LTED. Nine time-points between one and 40
weeks were assessed. The HumanWG-6 v3 Expression
BeadChip covers more than 48,000 transcript probes
and its annotation is publicly available. Raw data were
filtered and normalized using Robust Spline Normali-
zation method (RSN) within the Lumi package in Bio-
conductor [19]. Probes were discarded from further
analyses if they were not detected in any of the sam-
ples (detection P-value >1%). Differential gene expres-
sion analyses between the multiple time points were
performed in a pairwise fashion using the BRB Array
Tool [20]. Pathway analyses were performed on the
differentially expressed genes using Ingenuity Pathway
Analysis [21] (ArrayExpress Accession number, E-
MTAB-922).
Gene expression microarray analysis of breast tumors
Samples analyzed in this study were collected in the
IL1839/223 study, which received approval from an
institutional review board at each site and was con-
ducted in accordance with the 1964 Declaration of Hel-
sinki11 and International Conference on
Harmonization/Good Clinical Practice guidelines. Writ-
ten informed consent was obtained from each patient
before participation including approval for the biological
analysis of residual tissue samples [22]. Core-cut tumor
biopsies were collected using 14-gauge needles from 81
postmenopausal women with stage I to IIIB ER+ early
breast cancer before and after two weeks of anastrozole
treatment in the anastrozole only arm of a neoadjuvant
trial [22]. Total RNA was extracted using RNeasy (Qia-
gen, Crawley, UK). RNA quality was assessed using an
Agilent Bioanalyzer (Santa Clara, CA, USA). Samples
were analyzed only if their RNA integrity values were
greater than 5.0. RNA amplification, labeling, and hybri-
dization on HumanWG-6 v2 Expression BeadChips
were performed according to the manufacturer’s instruc-
tions (Illumina, San Diego, CA, USA). Raw data were
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filtered and normalized using the same method as per-
formed for the cell lines.
A proliferation metagene consisting of 101 genes was
developed by selecting the intersection of two prolifera-
tion clusters from two public breast cancer datasets
[23,24]. These two clusters were derived from each of
these two breast cancer datasets independently as the
smallest clusters that contained 95% of the genes pre-
viously reported to be associated with proliferation
[25-27]. Spearman correlation analyses were performed
to assess the relationship between the baseline expres-
sion of PDGFRb and change in the proliferation
metagene.
Proliferation assays
For proliferation assays, wt MCF7 cells were depleted of
steroids for three days (stripped) by culturing in DCC-
medium. Cells were subsequently seeded into 12-well
plates at a density of 1 × 104 cells per well in DCC med-
ium. LTED cells were treated similarly. Cells were left to
acclimatize for 24 hours and were then treated with
steroids or nilotinib (kindly provided by Novartis, Basel,
Switzerland) for six days with daily changes. The cell
number was determined using a Z1 Coulter counter
(Beckman Coulter, High Wycombe, UK). Error bars
represent ± standard error of the means (s.e.m.). Survi-
val assays were compared using two-way analysis of var-
iance (ANOVA) with Bonferroni correction.
SiRNA knockdown studies
For siRNA knockdown, cells were plated in DCC med-
ium on 96-well plates at a concentration of 2 × 103
(LTED) and 3 × 103 (MCF7) cells per well. After 24
hours cells were transfected with si control (non-target-
ing pool) or siRNA targeting ABL, PDGFRB or the com-
bination, using DharmaFECT 3 (Dharmacon, Horsham,
UK) according to the manufacturer’s protocol. The fol-
lowing day transfected cells were treated with DCC
medium alone or in the presence of E2 (0.01 nM). Cell
growth was determined using CellTiter-glo lumines-
cence assay (Promega, Southampton, UK) after 96
hours. Statistical analysis was performed using Student’s
T-test.
Immmunoblotting
Cell monolayers were washed with ice-cold PBS and
whole cell extracts generated as previously described
[28]. Equal amounts of protein (50 μg) were resolved by
SDS-PAGE and then subjected to immunoblot analysis.
Antigen-antibody interactions were detected with ECL-
reagent (Amersham, Amersham, UK). Phospho- and
total-proteins were detected using the following antibo-
dies: anti-ER (Novocastra, Milton Keynes, USA), anti-
AKT, anti-phospho AKT, anti-phospho PDGFR b, anti-
PDGFR b, anti-phospho Abl, anti-Abl (Cell Signaling
Technologies, Danvers, MA, USA), anti-actin, anti-phos-
pho ERK1/2 (Sigma, Gillingham, UK), anti-ERK1/2
(Santa Cruz, Santa Cruz, CA, USA).
Transcription assays
Cell lines were stripped for three days and seeded in 24-
well plates at a density of 7 × 104 cells per well for
MCF7 and 5 × 104 cells per well for LTED in DCC
medium. Twenty-four hours later monolayers were
transfected using Fugene 6 (Roche, Burgess Hill, UK),
with 0.1 μg of EREIItkluc (reporter) and 0.1 μg of
pCH110 (b-galactosidase for normalization) according
to the manufacturer’s protocol, before treatment with
the drugs indicated. After treatment for 24 hours the
luciferase (Promega, Southampton, UK) and b-galactosi-
dase (Galacto Star, Applied Biosystems, Bedford, MA,
USA) activities were measured using a luminometer
(TD20/20). Luciferase activity from triplicates was nor-
malized and was expressed relative to vehicle treated
control. Error bars represent ± s.e.m.
QRT-PCR
Cells were plated at a density of 4 × 104 cells per well in
24-well plates into DCC medium. After 24 hours mono-
layers were transfected with siRNA as described above.
RNA was extracted 48 hours later using the RNeasy kit
(Qiagen). The mRNA was quantified using a NanoDrop
1000 spectrometer and reverse transcribed into cDNA
using the SuperScript III First Strand Synthesis System
for RT-PCR (Invitrogen, Grand Island, NY, USA).
Expression levels of target genes were detected by qRT-
PCR using Assay-on-Demand primer/probe sets
KIAA0674 (Hs00391480-m1), ABL1 (Hs01104721-m1)
and PDGFRB (Hs01019583-m1).
ChIP analyses
LTED cells were treated with E2 alone or in combina-
tion with nilotinib for 45 minutes. Monolayers were
fixed with 1% formaldehyde for ten minutes at room
temperature and then quenched with glycine (0.125M).
Chromatin was purified as previously described [28].
Chromatin complexes were immunoprecipitated with
antibodies against ER (HC-20), AIB1 or CBP (Santa
Cruz). Immune-complexes were purified and resulting
DNA subjected to quantitative PCR analysis using SYBR
green (Applied Biosystems, Bedford, MA, USA) in the
presence of primers flanking the estrogen response ele-
ment (ERE) within the promoter region of GREB1 (for-
ward) 5’-GTGGCAACTGGGTCATTCTGA-3’ and
(reverse) 5’- CGACCCACAGAAATGAAAAGG-3’. Sta-
tistical analysis was performed using Student’s T-test.
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Results
PDGF/Abl canonical pathway is strongly associated with
adaptation to long term estrogen deprivation (LTED)
E-deprivation led to markedly decreased expression of
the proliferation metagene (MG) after one week but
near full recovery by nine weeks indicating resistance to
E-deprivation by this time point (Figure 1). Thereafter,
the expression of the MG remained stable. Moreover,
global assessment of gene expression revealed stabiliza-
tion of the gene signatures after this time-point. Based
on this observation, further analyses were restricted to a
triangular pairwise comparison of gene expression
between wt MCF7 cells in the presence of 1 nM E2
(modeling pre-treatment), one week post E-deprivation
(modeling early response to an AI) and at nine weeks
post E-deprivation (modeling acquired resistance to an
AI) (ArrayExpress Accession number, E-MTAB-922).
Comparison of gene expression in wt MCF7 cultured
in the presence of E2 versus week one cells showed that
1,970 genes were down-regulated and 1,653 genes were
up-regulated (P < 0.001/FDR = 0.004). The down-regu-
lated genes were mainly associated with metabolic and
cell cycle pathways (Table 1). The up-regulated genes
were associated with interferon and JAK/STAT
canonical pathways indicative of increased cell stress.
Comparison of week one versus week nine revealed 239
down-regulated genes and 236 up-regulated genes (P <
0.001/FDR = 0.03). Many of the down-regulated genes
were involved in immune response pathways. The major
up-regulated canonical pathways were involved in meta-
bolism and cell cycle apparently reversing many of the
changes seen by week one and consistent with the
increase of the expression of the proliferation metagene.
Given the relatively similar proliferation status of wt
MCF7 and week nine cells it was rationalized that com-
parison of wt MCF7 versus nine weeks E-deprivation
would negate the overriding effect of the proliferation
signature and unmask the underlying adaptive changes
associated with acquired resistance. This analysis
revealed 1,753 down-regulated genes and 1,758 up-regu-
lated genes (P < 0.001/FDR = 0.0048). All major up-
regulated canonical pathways were involved in classical
cell signaling including PI3K/AKT/p70S6 and IGF1. Of
particular interest the PDGF/Abl canonical pathway was
significantly elevated as early as one-week post E-depri-
vation (P = 1.94 × 10-4) and was the top adaptive path-
way at the point of resistance (P = 1.15 × 10-7). In order
























Figure 1 Temporal changes in the expression of the proliferation metagene. The dotted line represents the baseline proliferation
metagene for the wt MCF7 cells cultured in E2 (1 nM). E2, estradiol; wt, wild type.
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Table 1 Comparison of the canonical pathways
UP-REGULATED P value DOWN-REGULATED P value
Comparison A: Wt MCF7+E2 versus week 1 Comparison A: Wt MCF7+E2 versus week 1
Interferon signalling 2.79 E-
07
Purine metabolism 1.13 E-12
Molecular mechanisms of cancer 1.17 E-
05
Pyrimidine metabolism 2.11 E-10
JAK/STAT signalling 2.72 E-
05
Protein ubiquitination pathway 6.48 E-08
Germ cell-steroli cell junction signalling 2.76 E-
05
Role of BRCA1 in DNA damage response 6.92 E-08
Inositol phosphate metabolism 1.15 E-
04
Mitotic roles of polo-like kinase 5.72 E-07
IL-3 signalling 1.63 E-
04
Role of CHK proteins in cell cycle checkpoint control 1.41 E-06
PDGF signalling 1.94 E-
04
ATM signalling 3.06 E-06
Neuregulin signalling 2.15 E-
04
Cell cycle:G2/M DNA damage checkpoint regulation 1.23 E-05
Erythropoietin signalling 2.31 E-
04
Cleavage and polyadenylation of pre-mRNA 1.24 E-04
PI3K/AKT signalling 2.95 E-
05
Alanine and aspartate metabolism 5.15 E-04
Comparison B: Week 1 versus week 9 Comparison B: Week 1 versus week 9
Mitotic roles of polo-like kinase 4.71E-08 Antigen presentation pathway 8.88E-20
Role of CHK proteins in cell cycle checkpoint
control
2.08E-07 Interferon signalling 1.44E-17
ATM signalling 3.27E-07 Activation of IRF by cytosolic pattern recognition receptors 2.48E-10
Role of BRCA1 in DNA damage and response 8.75E-06 Role of pattern recognition receptors in recognition of bacteria and
viruses
2.37E-07
Hereditary breast cancer signalling 2.08E-05 Dendritic cell maturation 3.54E-06
Pyrimidine metabolism 3.34E-05 Allograft rejection signalling 7.64E-06
Cell cycle: G2/M DNA damage checkpoint
regulation
1.57E-04 Autoimmune thyroid disease signalling 1.04E-05
Graft-versus-host disease signalling 1.21E-05
Role of RIG1-like receptors in antiviral innate immunity 1.39E-05
Cross talk between dendritic cells and natural killer cells 2.02E-05
Comparison C: Wt MCF7+E2 versus week 9 Comparison C: Wt MCF7+E2 versus week 9
PDGF signalling 1.15E-07 Protein ubiquitination pathway 1.63 E-07
Molecular mechanisms of cancer 1.53E-07 Purine metabolism 6.49 E-07
Actin cytoskeleton signalling 4.92E-07 Pyrimidine metabolism 7.92 E-06
Integrin signalling 6.93E-07 Mitochondrial dysfunction 1.25 E-04
PI3K/AKT signalling 1.06E-06 Oxidative phosphorylation 2.47 E-04
EGF signalling 5.88E-06 Citrate cycle 4.79 E-04
FAK signalling 8.45E-06 Role of BRCA1 in DNA damage response 7.53 E-04
HGF signalling 1.23E-05 Lysine degradation 7.84 E-04
14-3-3 mediated signalling 1.30E-05
Neuregulin signalling 1.53E-05
Ephrin Receptor Signaling 1.66E-05
IGF-1 Signaling 1.85E-05
ILK Signaling 2.27E-05
Axonal Guidance Signaling 3.12E-05
JAK/Stat Signaling 6.14E-05
Insulin Receptor Signaling 6.17E-05
ATM, ataxia teleangiectasia mutated; BRCA1, breast cancer type 1 susceptibility protein; CHK, csk-homologous kinase; E2, estradiol; EGF, epidermal growth factor;
FAK, focal adhesion kinase; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor 1; IL-3, interleukin 3; ILK, integrin-linked kinase; IRF, interferon
regulatory factor; JAK, Janus kinase; PDGF, platelet-derived growth factor; PI3K, phosphatidylinositol 3-kinase; RIG1, retinoid-inducible gene 1; STAT, Signal
Transducer and Activator of Transcription;
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interrogated global gene transcription data from two
publically available global gene transcription data sets
from ER+ breast cancer cell lines (ZR-75.1, MDA MB
361 and HCC-1428) that had been adapted to LTED
[11,15]. The PDGF/Abl pathway was not significantly
altered within these data sets. Of note, unlike our LTED
cells many of these cell lines lost or significantly reduced
expression of ER during adaptation to estrogen depriva-
tion. In order to determine the validity of our findings
we, therefore, generated a further set of MCF7-LTED
cells and found that the PDGF/Abl pathway was once
again significantly increased indicating that acquisition
of this pathway may be context specific.
PDGFR expression is significantly associated with poor
anti-proliferative response to aromatase inhibition in
primary ER+ breast carcinomas
Prior to further molecular characterization of the PDGF/
Abl pathway as a putative mechanism of resistance and
potential target for therapy we sought evidence for its
likely clinical relevance by interrogating global gene
expression data from 81 ER+ patients who received the
AI anastrozole as neoadjuvant (pre-surgical) treatment
for 14 weeks. After two weeks on treatment, a second
biopsy was taken to generate paired gene expression
profiles during estrogen deprivation. PDGFRB showed
no significant correlation with known predictive markers
of hormone sensitivity such as ER or progesterone
receptor (PGR) at baseline. No significant correlation
with Ki67 or tumor size was observed. However,
PDGFRB associated negatively with the Global Index of
Dependence on Estrogen (GIDE) (r = 0.41 and P =
0.0002) [29] that reflects the overall transcriptional
response to E-deprivation. Furthermore, high PDGFRB
levels pre-treatment were significantly associated with a
poor response to the AI as measured using the prolifera-
tion metagene (P = 0.0006) (Figure 2A).
Additionally, pairwise comparison showed a significant
increase in PDGFRB and PDGFRL expression after two
weeks of estrogen deprivation (1.25-fold, P = 0.0003,
1.43-fold, P < 0.001), respectively (Figure 2B and 2C).
The increase in PDGFRB and PDGFRL in response to
neoadjuvant AI was further confirmed in an external
clinical dataset from patients treated with two weeks of
neoadjuvant letrozole (1.2-fold, P = 0.009 and 1.51-fold,
P < 0.001) [30].
The PDGF/Abl pathway acts as a driver of proliferation in
the LTED cells
Given the striking observation that PDGF/Abl was iden-
tified as the top adaptive pathway, expression levels of
proteins included in the PDGF/Abl signaling pathway
were investigated in the model systems. When com-
pared to the wt-MCF7, the LTED cells expressed higher
levels of PDGFRb Moreover, an up-regulation of both
PDGFRb and Abl phosphorylation was detected in the
LTED cell line. PDGFRa expression could not be
detected (Figure 3A).
To determine the relevance of single or combined
PDGFR and Abl inhibition on cell proliferation, short-
term (96 hours) siRNA knockdowns for the individual
proteins or their combination were performed in MCF7
and LTED cells. The efficiency of the siRNA knockdown
was assessed by qRT-PCR [See Additional file 1, Figure
S1]. In the MCF7 cells neither PDGFRb nor Abl knock-
down had a significant inhibitory effect on proliferation
in the presence or absence of E2. In contrast, knock-
down of Abl in LTED cells reduced proliferation signifi-
cantly in both the absence and presence of E2. An even
greater anti-proliferative effect was observed using a
siRNA knockdown of PDGFRb in LTED cells in the
absence and presence of E2. Of note, the combined
knock down of both targets suppressed proliferation
even further providing additional evidence of the rele-
vance of this canonical pathway in adaptation to LTED
(Figure 3B and 3C).
To establish the therapeutic relevance of the PDGF/
Abl pathway, we assessed the effect of nilotinib, a dual
PDGFR and Abl inhibitor on cell proliferation. Increas-
ing concentrations of nilotinib caused a slight but
noticeable decrease in proliferation (Figure 4A and 4B)
in wt MCF7 cells in the presence of 0.01 nM estradiol
(E2). However, this did not meet an IC50. Assessment
of the anti-proliferative effect of nilotinib in the absence
of E2 provided no further benefit compared to E2-depri-
vation alone. In contrast in the LTED model, nilotinib
inhibited cell proliferation significantly both in the pre-
sence and absence of E2. The IC50 dose of nilotinib in
this model (2 μM) is within the specific dose range
achievable in vivo [31].
Inhibition of PDGFR/Abl reduces ER protein levels
To elucidate the mechanism by which suppression of
PDGFR/Abl mediated the anti-proliferative effect seen,
wt MCF7 and LTED cells were treated with nilotinib in
the presence and absence of E2 and effects on down-
stream signaling were assessed. In the presence of niloti-
nib, phosphorylation of both AKT and ERK1/2 was
elevated irrespective of the presence of E2. Similarly,
nilotinib induced a slight but noticeable increase in Abl.
Strikingly, treatment with nilotinib suppressed the level
of ER in both cell lines although this was more notice-
able in the LTED cells (Figure 5).
Inhibition of PDGFR/Abl signaling suppresses ER-
mediated transcription in LTED cells
To elucidate the effect of PDGFR/Abl inhibition on ER-
mediated transcription, cells were transiently transfected
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with the ERE-luciferase reporter construct and treated
with nilotinib in the presence and absence of E2 (Figure
6). In the wt-MCF7 cells nilotinib had no effect on ER/
ERE-mediated transactivation in the absence of E2 and a
slight, but minimal inhibitory effect in the presence of





































































Figure 2 Expression of PDGFRb in clinical samples. A. Baseline expression of PDGFRb versus two-week change in the proliferation metagene
in 81 breast cancer patients. B. Expression changes of PDGFRb in response to AI treatment. C. Average percentage change in PDGFRb
expression pre- and post-AI treatment. AI, aromatase inhibitor; PDGFRb, platelet derived growth factor receptor b.
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Figure 3 Expression of PDGFRb and Abl in breast cancer cell lines. A. Wt MCF7 and LTED cells were screened for kinase expression using
western blotting. Cells were grown under basal conditions. Whole cell extracts were probed using antibodies against the indicated proteins. B.
Wt MCF7 and C. LTED cells were seeded into 96 well plates and transfected with small interfering RNA (siRNA) control, siPDGFRb, siAbl or the
combination of both and then treated ± E2 for 96 hours. Proliferation was measured using Cell Titre glo. Data are representative of three
individual experiments. Error bars express ± SEM * P < 0.05, ** P < 0.01. Abl, Abelson tyrosine kinase; E2, estradiol; LTED, long term estrogen
deprived; PDGFRb, platelet derived growth factor receptor b; SEM, standard error of the mean; siRNA small interfering RNA; Wt, wild type.
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mediated transactivation was significantly inhibited in
the absence of E2. Addition of E2 reduced the inhibitory
effect of nilotinib on ER-mediated transcription, data in
parallel with the effects on proliferation (Figure 6 C, D).
We next examined the effect of nilotinib on the
recruitment of ER together with its co-activators to the
promoter of GREB1 (an endogenous E-regulated gene)
using chromatin immunoprecipitation (ChIP). As ER/
ERE-mediated transcription was unaffected by nilotinib
in the wt-MCF7 we focused our attention on the LTED
cells. Nilotinib in the presence of E2 decreased the
recruitment of ER, AIB1 and the CREB binding protein
(CBP) to the ERE located within the GREB1 promoter
compared to E2 alone (Figure 6E).
Discussion
Resistance to endocrine therapy is a major clinical pro-
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Figure 4 Inhibition of PDGFRb and Abl using nilotinib suppresses growth of LTED cells. The endocrine sensitive cell line MCF7 (A) and
the resistant cell line LTED (B) were seeded on 12-well plates and incubated for six days with various concentrations of nilotinib ± E2. Cell
proliferation was determined using a Coulter counter. Data are representative of three individual experiments. Error bars express ± SEM of
triplicate samples. Two way ANOVA showed a significant difference in cell survival in the LTED cells in the presence or absence of E2 at doses of
1 uM and above P < 0.0001. Abl, Abelson tyrosine kinase; ANOVA, analysis of variance; E2, estradiol; LTED, long term estrogen deprived; PDGFRb,
platelet derived growth factor receptor b; SEM, standard error of the mean.
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along with others, have highlighted the role of cross-talk
between the ER and ERBB2/HER2 signaling pathways
leading to endocrine resistance as a result of ligand-
independent activation of the ER or by the generation of
an E-hypersensitive phenotype [10,14,32-35]. In the cur-
rent study, we used a novel strategy to try to identify
temporal changes in the transcriptome associated with
the acquisition of resistance to LTED. Using a prolifera-
tion MG we showed that proliferation recovered, that is,
resistance occurred, as early as nine weeks post E-
deprivation.
Comparison of the wt-MCF7 cells (modeling pre-
treatment) versus MCF7 cells after one week of E-depri-
vation (modeling a patient responding to an AI) high-
lighted proliferation and metabolic canonical pathways
as the most significantly down-regulated. This is in
keeping with previous short term clinical investigations
of AIs [29,36,37]. Of note, the JAK/STAT and interferon
canonical pathways were markedly up-regulated after
one week of E-deprivation. It has been shown that signal
transducer and activator of transcription 1 (STAT1) is
particularly important in activating IFN-g and its antitu-
mor effects. In addition to inhibiting proliferation and
survival, IFN-g enhances the immunogenicity of tumor
cells, in part, by enhancing the STAT1-dependent
expression of MHC proteins [38].
Changes in transcription profiles after one week of E-
deprivation with nine weeks of E-deprivation (modeling
a patient with acquired endocrine resistant disease) in
part reflected the reinstatement of proliferation, but also
showed that IFN signaling and several canonical path-
ways associated with immune recognition were down
regulated over that period. Clinical studies have shown
that in triple negative breast cancer impaired immune
response might be linked with the development of dis-
tant metastases. Indeed, high expression of an immune
response gene expression module was associated with a
significantly better outcome in two independent studies
[39,40]. Our data suggest that part of these immune sig-
natures may emanate from epithelial cells and not from
an inflammatory infiltrate.
Comparison of the wt MCF7 cells with nine weeks
post E-deprivation negated the overriding effect of the
proliferation signature and unmasked the underlying
adaptive changes associated with acquired resistance.
The major up-regulated canonical pathways were identi-
fied as all being classically associated with cell signaling
including PI3K/AKT/p70S6 and IGF1 all of which have
been associated with poor prognosis in previous studies
of ER+ breast cancer [41-46]. Of particular note, two
recent clinical studies TAMRAD [47] and BOLERO-2
[48] have reported substantially greater activity of the
mTOR inhibitor everolimus (RAD001) in the metastatic
setting after relapse on AI therapy.
Our most striking observation, however, was the





















Figure 5 Inhibition of PDGFRb and Abl with nilotinib reduces ER protein stability. Wt MCF 7 and LTED cells were treated with nilotinib (2
µM) ± E2 for 24 hours. Cell monolayers were subsequently harvested and whole cell extracts probed for the proteins indicated. Data shown are
representative of three independent experiments. Abl, Abelson tyrosine kinase; E2, estradiol; LTED, long term estrogen deprived; Wt, wild type.
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Figure 6 Inhibition of PDGFR/Abl suppresses ER/ERE-mediated transactivation. Cells were transfected with an artificial luciferase reporter
and treated as indicated. Luciferase activity was measured and normalized to DCC to quantify ER-transactivation. A and B show the effect of
nilotinib on ER-mediated transcription in wt-MCF7. C and D show the effect of nilotinib on ER-mediated transcription in LTED cells. The data
shown are representative of four individual experiments. Bars represent ± SEM of triplicate samples. E. ChIP analysis to determine ER, AIB1 and
CBP recruitment to the GREB1 promoter was performed. Cell monolayers were serum starved for 24 hours and treated for 45 minutes with E2 (1
nM) and nilotinib (4 μM) as indicated. Antibodies against total ERa, AIB1 and CBP were used to pull-down protein complexes and to assess their
recruitment to the ERE located in the GREB1 promoter by q-PCR. Data shown are representative of two independent experiments. Abl, Abelson
tyrosine kinase; AIB1, amplified in breast cancer 1; CBP, CREB binding protein; ChIP, chromatin immunoprecipitation; DCC, dextran charcoal-
stripped bovine serum; E2, estradiol; ER, estrogen receptor; ERE, estrogen response element; LTED, long term estrogen deprived; SEM, standard
error of the mean; wt, wild type.
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pathway was elevated as early as one week post E-depri-
vation. Although the over riding effect of E-deprivation
after one week was suppression of proliferation, path-
ways such as PDGF/Abl, neuregulin (Her2) and PI3
kinase were up-regulated and may be indicative of early
adaptive responses pre-dating cell growth. Surprisingly,
PDGF/Abl became the top adaptive pathway at the
point of resistance superseding both the neuregulin and
PI3 kinase canonical pathways, both of which have been
previously reported to be strongly associated with endo-
crine resistance [15].
PDGF receptors (PDGFR) contain an intracellular tyr-
osine kinase domain whose activation is dependent on
binding of PDGF resulting in stimulation of several
intracellular pathways, leading to cell proliferation and
survival [49]. PDGF can promote tumor growth via
autocrine stimulation of malignant cells, overexpression
or overactivation of PDGFRs, or by stimulating tumor
angiogenesis. For this reason, targeting PDGF signaling
has become of interest for the development of antican-
cer therapeutics. Two main approaches have been taken
to inhibit PDGFR signaling in cancer: direct targeting of
tumor cells proliferating in response to PDGF signaling
or indirect inhibition of tumor growth by targeting peri-
cytes to decrease angiogenesis [49]. Abl is a Src-like
nonreceptor protein kinase that acts down-stream of the
PDGFR. Abl is involved in the regulation of cell prolif-
eration, apoptosis, adhesion, cell migration and stress
response [50,51]. The existence of C-terminal DNA-
binding motifs and nuclear localization signals enables
Abl to shuttle between cytoplasmic and nuclear com-
partments [52,53]. Activating translocations of ABL,
such as BCR-ABL, are pivotal for the development of
chronic myelogenous leukemia [54].
To determine the clinical significance of our finding
we used global gene transcription data from a cohort
of patients with ER+ primary breast cancer before and
after two weeks of neoadjuvant AI therapy. Notably
PDGFRB and PDGFRL expression was increased after
two weeks of E-deprivation (Figure 2B). Moreover, low
PDGFRB levels pre-treatment were associated with a
better response to the AI. This would support the pos-
sibility that expression of PDGFRb may be an early
marker of de novo and/or acquired endocrine resis-
tance. In support of our finding a recent clinical study
showed that elevated levels of stromal PDGFRb were
associated with a poor prognosis in breast cancer
patients [55].
To investigate the role of PDGF/Abl signaling during
adaptation to LTED we selected the dual PDGFR/Abl
kinase inhibitor nilotinib. Treatment of the wt MCF7
cells in the presence of E2 modeling a patient at primary
diagnosis showed that nilotinib as a monotherapy
caused a concentration-dependent decrease in
proliferation but this was far less compared with E-
deprivation alone. In order to model the effect of niloti-
nib in patients who have relapsed on an AI and for
whom treatment has ceased we treated the LTED cells
with 0.01 nM E2. In keeping with our previous data [56]
we showed that E2 caused an increase in proliferation
(1.85-fold) although the magnitude of the response was
far less than that seen in the MCF7 cells (12-fold). The
LTED cells were significantly sensitive to nilotinib in the
presence of E2. The IC50 dose of nilotinib in this model
was within the range of plasma levels achieved clinically.
Most strikingly, proliferation was substantially lower
with nilotinib in the absence of E2. This suggests that in
the clinical setting nilotinib may be useful in combina-
tion with an AI to delay the onset of resistance or
indeed to prolong the efficacy of the AI in the meta-
static setting.
In order to determine whether PDGFRb or Abl was
dominant in the LTED phenotype, we used siRNA
knockdown. Surprisingly both kinases appeared integral
to the phenotype, although suppression of PDGFRb
inhibited proliferation to a greater degree. Assessment
of the effect of nilotinib on downstream signaling in
both the wt MCF7 and the LTED in the presence and
absence of E2 showed that nilotinib increased both AKT
and ERK1/2 phosphorylation. Studies with dasatinib,
which targets Src-family kinases and Abl have shown
similar increases in signaling via these pathways. It has
been postulated that this might be indicative of an early
resistance mechanism to inhibition of these non-recep-
tor tyrosine kinase pathways [57].
Of particular note, nilotinib significantly decreased ER
levels. It has been demonstrated using transient trans-
fection that Abl regulates ER protein stability via phos-
phorylation of tyrosine 52 and 219 [58]. Similarly, Abl
has been shown to phosphorylate AIB1, a nuclear co-
activator for ER, providing further evidence for the role
of Abl in modulating ER genomic function [59]. As the
LTED cells remain dependent on the ER for prolifera-
tion [12] we hypothesized that inhibition of Abl may
suppress ER-mediated transcription. Indeed, we were
able to demonstrate that nilotinib significantly reduced
ER/ERE transactivation as a result of decreased recruit-
ment of ER, AIB1 and CBP (Figure 6).
These data suggest that PDGFR/Abl signaling may
provide a therapeutic target in ER+ breast cancer.
Recently, the clinical significance of impeding c-kit and
PDGFR in combination with aromatase inhibition has
been addressed in two single arm clinical trials in ER+
breast cancer patients [60,61]. In the first pre-operative
study ER+ patients were treated with letrozole plus ima-
tinib, a c-Kit/PDGFR/Abl receptor tyrosine kinase inhi-
bitor, for three months. Of the ten evaluable patients,
nine achieved clinical partial response and one had
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stable disease. In a second single arm study, postmeno-
pausal women with ER+ disease and no prior endocrine
therapy for metastatic breast cancer who expressed
PDGFR and/or c-kit, were treated with letrozole plus
imatinib. Partial response was achieved in seven patients
(15.6%) and stable disease was observed in 20 patients
(44%). The disadvantage of these studies is that the AI
alone was not assessed and, therefore, it is impossible to
ascertain the benefit gained by the combination. To
address this, a two arm study comparing an AI versus
AI plus imatinib or nilotinib would be required in
which patients with ER+/PDGFR+ breast cancer would
be eligible.
Conclusions
Using temporal global gene expression data together
with functional analysis we have identified a novel inter-
action between ER and the PDGF/Abl signal transduc-
tion pathway that occurs during adaptation to LTED
and which appears partly responsible for the resistant
phenotype. One of the major limitations of this study is
the use of a single cell line model of acquired resistance
to E-deprivation and as such these finding may be con-
text specific. However, we were able to confirm the clin-
ical relevance of these in vitro observations in two
independent and heterogeneous cohorts of patients trea-
ted with an AI.
Taken together these data suggest that PDGFRb may
provide a novel biomarker of early resistance to AI ther-
apy and with further in vitro and in vivo validation may
prove to be a novel therapeutic target in treatment and/
or avoidance of endocrine resistance in certain patient
populations.
Additional material
Additional file 1: Figure S1: siRNA knockdown of PDGFRb and Abl
reduces mRNA expression. Cells were transfected with siRNA against
PDGFRb, Abl or the combination of the two. Forty-eight hours after
transfection mRNA was extracted, quantified and reverse transcribed.
Expression levels of genes were detected using qRT-PCR. Error bars
represent ± SEM.
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